about glioresolve

Glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. Effective precision medicine therapies are thus urgently required.

The pan-European, academic & private sector GLIORESOLVE Doctoral Network (DN) is funded by the European Union’s Horizon Europe programme under the Marie Skłodowska-Curie DN initiative. The project started in 2022 and over the next four years, will train 10 innovative, creative and entrepreneurial PhD students with a specific focus on GBM research. Overall, GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease.